John M Leonard Intellia Therapeutics, Inc. (NTLA) insider trading activity

John M Leonard is President and CEO of Intellia Therapeutics, Inc.. Currently has a direct ownership of 1.08 Million shares of NTLA, which is worth approximately $8.69 Million. The most recent transaction as insider was on Feb 09, 2021, when has been sold 28,043 shares (Common Stock) at a price of $75.0 per share, resulting in proceeds of $2,103,225. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.08M

14.45% 3M change

12.19% 12M change

Total Value Held $8.69 Million

JOHN M LEONARD Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 09 2021	SELL Open market or private sale	$2,103,225 $75.0 p/Share	28,043 Reduced 4.07%	660,536 Common Stock
Feb 09 2021	BUY Exercise of conversion of derivative security	$387,384 $6.83 p/Share	56,718 Added 7.61%	688,579 Common Stock
Feb 05 2021	SELL Open market or private sale	$1,558,680 $67.94 p/Share	22,942 Reduced 3.5%	631,861 Common Stock
Feb 05 2021	BUY Exercise of conversion of derivative security	$536,000 $13.4 p/Share	40,000 Added 5.76%	654,803 Common Stock
Feb 03 2021	SELL Open market or private sale	$4,919,560 $72.5 p/Share	67,856 Reduced 9.94%	614,803 Common Stock
Feb 03 2021	BUY Exercise of conversion of derivative security	$2,145,710 $18.33 p/Share	117,060 Added 15.23%	651,661 Common Stock
Feb 01 2021	SELL Open market or private sale	$7,048,280 $64.14 p/Share	109,889 Reduced 16.27%	565,599 Common Stock
Feb 01 2021	BUY Exercise of conversion of derivative security	$3,090,000 $15.45 p/Share	200,000 Added 25.04%	598,814 Common Stock
Jan 05 2021	SELL Open market or private sale	$348,511 $55.86 p/Share	6,239 Reduced 1.3%	475,488 Common Stock
Dec 31 2020	BUY Exercise of conversion of derivative security	-	14,375 Added 2.9%	481,727 Common Stock
Nov 27 2020	SELL Open market or private sale	$1,347,500 $38.5 p/Share	35,000 Reduced 6.97%	467,352 Common Stock
Nov 27 2020	BUY Exercise of conversion of derivative security	$575,400 $16.44 p/Share	35,000 Added 6.7%	487,352 Common Stock
Nov 25 2020	SELL Open market or private sale	$1,800,000 $36.0 p/Share	50,000 Reduced 9.66%	467,352 Common Stock
Nov 25 2020	BUY Exercise of conversion of derivative security	$341,500 $6.83 p/Share	50,000 Added 8.81%	517,352 Common Stock
Nov 16 2020	SELL Open market or private sale	$680,000 $34.0 p/Share	20,000 Reduced 4.1%	467,352 Common Stock
Nov 16 2020	BUY Exercise of conversion of derivative security	$291,600 $14.58 p/Share	20,000 Added 3.94%	487,352 Common Stock
Nov 04 2020	SELL Open market or private sale	$1,300,000 $26.0 p/Share	50,000 Reduced 9.66%	467,352 Common Stock
Nov 04 2020	BUY Exercise of conversion of derivative security	$341,500 $6.83 p/Share	50,000 Added 8.81%	517,352 Common Stock
Oct 07 2020	SELL Open market or private sale	$109,150 $21.83 p/Share	5,000 Reduced 1.06%	467,352 Common Stock
Oct 07 2020	BUY Exercise of conversion of derivative security	$34,150 $6.83 p/Share	5,000 Added 1.05%	472,352 Common Stock

Also insider at

IQV

IQVIA HOLDINGS INC. Healthcare

Director

JML

John M Leonard

President and CEO

Durham, NC

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NTLA shares.

Notify only if

Value

Insider Trading

Get notified when an Intellia Therapeutics, Inc. insider buys or sells NTLA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Intellia Therapeutics, Inc.

Track Activities on NTLA

Account